A group of outside experts working inside CDRH has pinpointed significant variability in how FDA approves new clinical trials and is proposing new agency metrics to improve the investigational device exemption process.
Efforts by participants in the device center’s entrepreneurs-in-residence program are still under way, but FDA officials have so far been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?